#GI25 @ascocancer.bsky.social
For #colorectalcancer, there are many great abstracts-so this is just a few to🔦:
Pre-op:
1⃣@CQvortrup🗣️a Single-cycle of neoadj pembro for Stage I-III MMRdef CRC, Oral Abs 19
2⃣@jonathanloree🗣️using ctDNA🩸to support Non-Op management in rectal cancer, Oral Abs 20

#GI25 @ascocancer.bsky.social
The BIG trial in #colorectalcancer will be Scott Kopetz 🗣️BREAKWATER, the 1st line R-Ph3 trial of encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant met CRC, Oral Abs 16

#GI25 @ascocancer.bsky.social
And 3 immunotherapy trials in #MCRC:
1⃣Thierry Andre🗣️the LBA of Ipi-Nivo vs Nivo of dMMR mCRC, ABS LBA143
2⃣ Marwan Fakih🗣️a Ph2 trial of BOT +/- Bal in MSS mCRC (no liver mets), Oral Abs 23
3⃣Joel R Hecht🗣️a Ph2 trial of a personalized Neo-Ant IO for MSS CRC, Abs LBA13

#GI25 @ascocancer.bsky.social
Finally, two additional abstracts to watch for in #cholangiocarcinoma:
1⃣Dr. Priyanshi Shah🗣️Long-term outcomes for MSI-H BTC patients on immunotherapy, Abs 592; Post#C18
2⃣Dr. Christos Fountzilas🗣️🎯FGFR in the Ph2 trial of Tinengotinib for BTC Pts, Abs 608; Post#D9

#GI25 @ascocancer.bsky.social
3⃣abstracts🔬outcomes of Pts with specific🧬alterations in #cholangiocarcinoma:
1⃣&2⃣look at MDM2amp BTC:
➡️Dr. Iyer, Abs 544; Post#A22
➡️Teresa Macarulla, Abs 615, Post#D16
3⃣Richard Kim🗣️Real-World OS in BTC Pts with IDH1mut or FGFR2fus + BTC, Abs 548; Post#A26

Dear Colleagues,
Wishing you hashtag#MerryChrismas2024 & Happy Holidays from All of us at OncoAlert 🚨

@elisaagostinetto.bsky.social
@drjnaidoo.bsky.social
@lymphomadoc.bsky.social
@realbowtiedoc.bsky.social
@stephenvliu.bsky.social
@drlestercoll.bsky.social
@erikahamilton9.bsky.social